Comparison of the rate dependent effects of dofetilide and ibutilide in the newborn heart

PACE - Pacing and Clinical Electrophysiology

Volumn 24, Issue 5, 2001, Pages 816-823

  Pickoff, Arthur S ^a   Stolfi, Adrienne ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Class III antiarrhythmic agent; Dog; Electrophysiology; Monophasic action potential duration; Newborn

Indexed keywords

ANTIARRHYTHMIC AGENT; DOFETILIDE; IBUTILIDE FUMARATE; PENTOBARBITAL; PROPRANOLOL; SILVER CHLORIDE;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG RESPONSE; ELECTRODE; EPICARDIUM; HEART ATRIUM; HEART CYCLE; HEART ELECTROPHYSIOLOGY; HEART RATE; HEART VENTRICLE; NEWBORN; NONHUMAN; SUPRAVENTRICULAR TACHYCARDIA; VAGOTOMY;

EID: 0035002068     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.2001.00816.x     Document Type: Article

References (34)

1. 1. Vaughan Williams EM, Classification of antiarrhythmic drugs. In E Sandoe, et al. (eds.): Symposium on Cardiac Arrhythmias. Sodertalje Sweden, AB Astra, 1970, pp. 440-469.
2. 2. Singh BN. Current antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility. J Cardiovasc Electrophysiol 1999: 10:283-301.
3. 3. Nattel S, Singh BN. Evolution, mechanisms, and classification of antiarrhythmic drugs; Focus on class III actions. Am J Cardiol 1999; 84:11R-19R.
4. 4. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990; 81:686-690.
5. 5. Wang J, Bourne GW, Wang Z, et al. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use dependent effects on refractoriness. Circulation 1993; 88:1030-1044.
6. + current through a nifedipine inhibited inward channel. J Pharmacol Exp Ther 1998; 286:9-22.
7. + current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992; 262:99-108.
8. 8. Foster RH, Wilde MI, Markham A. Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs 1997; 54:312-330.
9. 9. Ellenbogen KA, Clemo HF, Stambler BS, et al. Efficacy of ibutilide for termination of atrial fibrillation and flutter. Am J Cardiol 1996; 78(Suppl. 8A):42-45.
10. 10. Murray KT. Ibutilide. Circulation 1998; 97:493-497.
11. 11. Pfammatter J-P, Paul T. New antiarrhythmic drug in pediatric use: Sotalol. Pediatr Cardiol 1997; 18:28-34.
12. 12. Paul T, Guccione P. New antiarrhythmic drugs in pediatric use: Amiodarone. Pediatr Cardiol 1994; 15:132-138.
13. 13. Perry JC, Fenrich AL, Hulse JE, et al. Pediatric use of intravenous amiodarone: Efficacy and safety in critically ill patients from a multicenter protocol. J Am Coll Cardiol 1996; 27:1246-1250.
14. 14. Franz MR. Current status of monophasic action potential recording: Theories, measurements, and interpretations. Cardiovasc Res 1999; 41:25-40.
15. 15. Dise T, Stolfi A, Yamasaki S, et al. Electropharmacodynamics of N-acetylprocainamide in the immature mammalian heart. Evidence for a prominent class III effect in the newborn. J Cardiovasc Pharmacol 1991; 17:96-101.
16. 16. Xu H, Villafane J, McCormack J, et al. Comparisons of the electrophysiological effects of intravenous sotalol and propranolol on the immature mammalian heart. J Cardiovasc Pharmacol 1989; 13:925-929.
17. 17. Pickoff AS, Singh S, Flinn CJ, et al. Dose dependent electrophysiologic effects of amiodarone in the immature canine heart. Am J Cardiol 1983; 52:621-625.
18. 18. Wallace AA, Stupienski RF III, Brookes LM, et al. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs. J Cardiovasc Pharmacol 1991; 18:687-695.
19. 19. Gwilt M, Blackburn KJ, Burges RA, et al. Electropharmacology of dofetilide, a new class III agent, in anesthetized dogs. Eur J Pharmacol 1992; 215:137-144.
20. 20. Buchanan LV, LeMay RJ, Walters RR, et al. Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model. J Cardiovasc Electrophysiol 1996; 7:113-119.
21. 21. Gjini V, Schreieck J, Korth M. et al. Frequency dependence in the action of the class III antiarrhythmic drug dofetilide is modulated by altering L-type calcium current and digitalis glucoside. J Cardiovasc Pharmacol 1998; 31:95-100.
22. Kr . Implications for torsade de pointes and reverse use-dependence, Circulation 1996; 93:407-411.
23. 23. Buchanan LV, LeMay RJ, Gibson JK. Comparison of the class III agents d,l sotalol HCl and ibutilide fumarate for atrial reverse use dependence and antiarrhythmic effects, PACE 1996; 19(Pt. II):687.
24. 24. Cimini MG, Brunden MN, Gibson JK. Effects of ibutilide fumarate, a novel antiarrhythmic agent, and its enantiomers on isolated rabbit myocardium. Eur J Pharmacol 1992; 222:93-98.
25. 25. Baskin EP, Lynch JJ Jr. Differential atrial versus ventricular activities of Class III potassium channel blockers. J Pharmacol Exp Ther 1998; 285:135-142.
26. 26. Nattel S, Liu L, St-Georges D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res 1998; 37:627-635.
27. 27. Todt H, Zojer N, Schütz W. Differential effect of dofetilide on ventricular repolarization during steady state and during restitution in vivo. J Cardiovasc Pharmacol 1994; 24:1010-1013.
28. 28. Lande G, Maison-Blanche P, Fayn J, et al. Dynamic analysis of dofetilide-induced changes in ventricular repolarization. Clin Pharmacol Ther 1998; 64:312-321.
29. 29. Chen Y-J, Hsieh M-H, Chiou C-W, et al. Electropharmacologic characteristics of ventricular proarrhythmia induced by ibutilide. J Cardiovasc Pharmacol 1999; 34:237-247.
30. + channel expression in the developing mammalian myocardium, J Neurobiol 1998; 37:37-59.
31. to in canine epicardium. Am J Physiol 1995; 268:H2513-2521.
32. 32. Barajas-Martinez H. Elizalde A, Sanchez-Chapula JA. Developmental differences in delayed rectifying outward current in feline ventricular myocytes. Am J Physiol 2000; 278:H484-H492.
33. 33. Xu Y-Q, Pickoff AS, Clarkson CW. Evidence for developmental changes in sodium channel inactivation gating and sodium channel block by phenytoin in rat cardiac myocytes. Circ Res 1991; 69:644-656.
34. 34. Jeck CD, Boydan PA. Age-related appearance of outward currents may contribute to developmental differences in ventricular repolarization. Circ Res 1992; 71:1390-1403.